-
Dr. Jianxiang Wang: Leading Research, Continuous Innovation! Focusing on the Practice and Vision of CAR-T Cell Therapy in China
In early September 2024, the 5th Tianjin International Lymphoma Conference was held from September 6 to 8, amid the golden season of autumn. This conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, creating a high-end academic platform for international exchange and collaboration. During the event, Hematology Frontier invited Dr.…
-
Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference
From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for international academic exchange and cooperation. During the event, Hematology Frontier invited Dr. Wei Sang from The Affiliated Hospital of Xuzhou Medical University…
-
JOH | Predictive Factors for Hepatitis Flares after Stopping Nucleos(t)ide Analogs
Hepatitis flares are common and potentially harmful after stopping NAs, making it essential to identify predictive factors for risk stratification and post-discontinuation follow-up. This multicenter cohort study involved CHB patients…
-
Expert Insights from the 2024 ESMO Congress l The INSPIRE Study Shines on the International Stage Once Again
The European Society for Medical Oncology Congress 2024(ESMO 2024) opened on September 13, in Barcelona,Spain. Lung cancer remains one of the key areas of focus,with several groundbreaking studies presented at the conference. Oncology Frontier invited Dr.Yuankai Shi, principal investigator of the INSPIRE study from the Cancer Hospital Chinese Academy of Medical Sciences,to share the latest…
-
Gut丨MED12 Loss Activates Retrotransposons to Enhance Immunotherapy Sensitivity in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by high mortality rates and limited treatment options. Immunotherapy, particularly immune checkpoint blockade (ICB), has shown remarkable efficacy in treating cancers like melanoma and non-small cell lung cancer. However, many PDAC patients exhibit poor responses to ICB, mainly due to the tumor’s low immunogenicity…
-
Wetland Virus: Chinese Scientists Discover a New Tick-Borne Virus
On September 4, a team of Chinese researchers led by Dr. Wei Liu and Dr. Hao Li from the State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, along with Ningyi Jin’s team from the Changchun Institute of Veterinary Medicine, published a groundbreaking study in the New England Journal of Medicine…
-
SOHO 2024丨Dr. Peihua Lu: CD7 CAR-T Cell Therapy Opens New Pathways to Cure, Reshaping the Future of T-Cell Malignancy Treatment
The 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4 to 7, 2024. It brought together leading experts in hematologic oncology from around the world to discuss the latest research findings and explore new treatment strategies. Among the numerous topics discussed, the treatment of T-cell…
-
Dr. Hongmei Jing: A New Era of Precision Medicine in Lymphoma Treatment
With the rapid advancements in medical technology and deeper insights into the mechanisms of lymphoma, traditional chemotherapy is gradually giving way to a new era of precision-targeted and immunotherapies. Innovative drugs are emerging like bamboo shoots after the rain, offering personalized treatment paths tailored to lymphoma patients. This marks the dawn of a new era…
Connecting Medical Expertise through Media